2023-04-24 07:30:47 ET
- Can-Fite BioPharma ( NYSE: CANF ) has announced executive changes to support the Company’s continued success in advancing its pipeline toward commercialization through two pivotal Phase III trials in psoriasis and liver cancer.
- Motti Farbstein will take additional responsibility of Chief Executive Officer ( CEO ) while continuing to serve as the Company’s Chief Financial Officer ( CFO ).
- Dr. Ilan Cohn, the Company’s Co-Founder and former Chairman, remains on the Board and will continue to guide the Company’s intellectual property strategy and portfolio.
- These executive changes go into effect on June 30, 2023.
- Source: Press Release
For further details see:
Can-Fite announces new management structure as advanced stage pipeline moves toward commercialization